Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Biogen, Inc. (NQ: BIIB )

274.04 USD +1.93 (+0.71%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 7, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Biogen, Inc.

< Previous 1 2 3 4 5 6 7 8 9
...
58 59 Next >
Biogen Receives Honorable Mention From Fast Company's World Changing Ideas Awards
Tags World Changing Ideas Awards CSR Awards Sustainability Awards
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Biogen Provides Regulatory Update on the Supplemental Biologic License Application (sBLA) for Subcutaneous Administration of TYSABRI® (natalizumab)
From GlobeNewswire News Releases
Biogen Releases 2020 Year in Review Demonstrating Its Commitment to Transparency and Progress across Environmental, Social and Governance Metrics
From GlobeNewswire News Releases
Biogen Releases 2020 Year in Review Demonstrating Its Commitment to Transparency and Progress across Environmental, Social and Governance Metrics
Tags Biogen Corporate Social Responsibility Transparency
From 3BL Media: Corporate Social Responsibility, Energy and Health News
New Project to Help Community Health Clinics Address Climate Risks Launched by Biogen, Americares and Harvard Chan C-CHANGE
Tags Improving Healthcare Access Health & Healthcare Public Health
From 3BL Media: Corporate Social Responsibility, Energy and Health News
WBCSD Member Companies Launch New Project to Advance Global Health and Wellbeing
Tags NASDAQ:BIIB Public Health Partnerships
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Global Dementia Drugs Market Expected to Exceed $19.6 Billion In 2026
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Global Dementia Drugs Market Expected to Exceed $19.6 Billion In 2026
FinancialNewsMedia.com News Commentary 
From PR Newswire
18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer's Disease Published in Peer-Reviewed Jo
Lecanemab Phase 3 Clarity AD Clinical Trial Completed Enrollment 
From PR Newswire
Biogen Advances Leading Research in Spinal Muscular Atrophy (SMA) with New Data at AAN 2021 Exploring Opportunities to Improve Outcomes for Patients
From GlobeNewswire News Releases
New Data at AAN 2021 from Across Biogen’s MS Portfolio Demonstrate Positive Impact of Treatment on People Living with Relapsing Multiple Sclerosis
From GlobeNewswire News Releases
Biogen Grows Presence in China with the Approval of TECFIDERA® (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis
From GlobeNewswire News Releases
Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021
From GlobeNewswire News Releases
The Road to a 100% Electric Vehicle Fleet
Tags Electric Vehicles NASDAQ:BIIB Green Infrastructure
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Sage Therapeutics and Biogen Announce SAGE-324 Phase 2 Placebo-Controlled KINETIC Study in Essential Tremor Met Primary Endpoint
Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today reported topline results from the Phase 2 KINETIC Study evaluating SAGE-324 in the treatment of people with essential tremor... 
From Business Wire News Releases
Biogen Announces Two New Nominees for Election to Board of Directors
From GlobeNewswire News Releases
Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement for Proposed Biosimilar Currently in Phase 3 With the Potential to Treat Moderate to Severe Rheumatoid Arthritis
From GlobeNewswire News Releases
The European Commission Grants Marketing Authorization for New Subcutaneous Administration of TYSABRI® (natalizumab) to Treat Relapsing-Remitting Multiple Sclerosis
From GlobeNewswire News Releases
Biogen Announces Plans to Build a New, State-of-the-Art Gene Therapy Manufacturing Facility in Research Triangle Park, North Carolina
From GlobeNewswire News Releases
Biogen Inc. (NASDAQ:BIIB) Long Term Investor Alert: Investigation of Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 03/02/2021 -- Certain directors of Biogen Inc are under investigation concerning potential breaches of fiduciary duties. 
From SBWire - Latest Press Releases
Telemedicine and Wellness Apps Have Showcased Tremendous Growth Due To Pandemic
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Telemedicine and Wellness Apps Have Showcased Tremendous Growth Due To Pandemic
- Financialnewsmedia.com News Commentary 
From PR Newswire
The Partnership, Inc. Launches New North Carolina Mid-Career Leadership Accelerator Program
Tags Biogen Responsible Business & Employee Engagement North Carolina Mid/Career Leadership Accelerator Program
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Life Science Cares and Biogen Foundation Help Launch Food For Free’s Just Eats Program
From GlobeNewswire News Releases
Life Sciences Cares & Biogen Foundation Help Launch Food for Free's Just Eats Program
Tags Zero Hunger Corporate Contributions Partnerships
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Biogen Announces the Expiration Date Results of Its Cash Tender Offer
From GlobeNewswire News Releases
Biogen Announces the Expiration Date Results of Its Private Exchange Offer
From GlobeNewswire News Releases
Biogen and LabCentral Award Two Golden Tickets to Local and Innovative Science Startups
From GlobeNewswire News Releases
Biogen Announces the Pricing Terms of its Cash Tender Offer
From GlobeNewswire News Releases
Biogen Announces the Pricing Terms of Its Private Exchange Offer
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
58 59 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.